Cingulate is trading at $5.14, up +8.95% in after-hours trading, with no clear company-specific catalyst identified.

  • The November 3, 2026 regular session closed at $4.72, down 6.16%.
  • A market source reported no headlines for November 3. Cingulate announced completion of its final FDA-required food-effect study on November 2, but available coverage does not establish it caused the after-hours rise.